BiotechTube

Romosozumab + Bisphosphonate

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteogenesis Imperfecta

Conditions

Osteogenesis Imperfecta

Trial Timeline

Apr 22, 2024 → Aug 25, 2027

NCT ID
NCT05972551

About Romosozumab + Bisphosphonate

Romosozumab + Bisphosphonate is a phase 3 stage product being developed by Amgen for Osteogenesis Imperfecta. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05972551. Target conditions include Osteogenesis Imperfecta.

What happened to similar drugs?

1 of 6 similar drugs in Osteogenesis Imperfecta were approved

Approved (1) Terminated (2) Active (3)
✅Teriparatide (FORTEO) + PlacebosEli LillyApproved
🔄Zoledronic AcidNovartisPhase 3
❌DenosumabAmgenPhase 3
❌Denosumab + Alternative osteoporosis medicationsAmgenPhase 3
🔄setrusumabUltragenyx PharmaceuticalPhase 3
🔄Bisphosphonate + SetrusumabUltragenyx PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05972551Phase 3Recruiting

Competing Products

16 competing products in Osteogenesis Imperfecta

See all competitors
ProductCompanyStageHype Score
Teriparatide (FORTEO) + PlacebosEli LillyApproved
43
Zoledronic AcidNovartisPhase 2
35
Zoledronic AcidNovartisPhase 2
35
Zoledronic AcidNovartisPhase 3
40
RomosozumabAmgenPhase 1
29
DenosumabAmgenPhase 3
32
Denosumab + Alternative osteoporosis medicationsAmgenPhase 3
32
FresolimumabSanofiPhase 1
29
SAR439459 + PlaceboSanofiPhase 1
21
BPS804Ultragenyx PharmaceuticalPhase 2
29
SetrusumabUltragenyx PharmaceuticalPhase 2/3
36
SetrusumabUltragenyx PharmaceuticalPhase 2
21
BPS804Ultragenyx PharmaceuticalPhase 2
21
setrusumabUltragenyx PharmaceuticalPhase 3
38
setrusumab + zoledronic acid (optional)Ultragenyx PharmaceuticalPhase 2
29
Bisphosphonate + SetrusumabUltragenyx PharmaceuticalPhase 3
38